What is Corcept Therapeutics' operating income?

Corcept Therapeutics' total operating income in 2025 was $44.80 million, based on the following breakdown: Total Gross Profit: $748.43 million Total Operating Expenses: $703.63 million

Corcept Therapeutics (CORT) Financials

$111.74 -1.06 (-0.94%)

As of 03:06 PM Eastern

Compare

Annual Income Statements for Corcept Therapeutics

This table shows Corcept Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-6.41	8.14	129	75	94	106	113	101	105	140	98
Consolidated Net Income / (Loss)	-6.41	8.14	129	75	94	106	113	101	106	141	100
Net Income / (Loss) Continuing Operations	-6.41	8.14	129	75	94	106	113	101	106	141	100
Total Pre-Tax Income	-6.41	8.14	53	92	117	132	125	116	125	161	66
Total Operating Income	-3.44	10	53	89	112	128	124	113	107	137	45
Total Gross Profit	49	79	156	246	301	348	361	396	476	664	748
Total Revenue	50	81	159	251	306	354	366	402	482	675	761
Operating Revenue	50	81	159	251	306	354	366	402	482	675	761
Total Cost of Revenue	1.36	2.06	3.55	5.22	5.50	5.58	5.28	5.39	6.48	11	13
Operating Cost of Revenue	1.36	2.06	3.55	5.22	5.50	5.58	5.28	5.39	6.48	11	13
Total Operating Expenses	52	69	103	157	189	220	236	284	369	527	704
Selling, General & Admin Expense	37	45	62	81	100	105	122	153	184	280	449
Research & Development Expense	15	24	40	75	89	115	114	131	184	247	255
Total Other Income / (Expense), net	-2.97	-2.04	-0.05	2.66	5.07	3.40	0.53	3.56	17	25	22
Income Tax Expense	0.00	0.00	-76	17	22	26	12	15	18	20	-33
Basic Earnings per Share	($0.06)	$0.07	$1.14	$0.65	$0.82	$0.92	$0.97	$0.95	$1.02	$1.35	$0.95
Weighted Average Basic Shares Outstanding	106.88M	110.57M	113.53M	115.34M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M	103.86M
Diluted Earnings per Share	($0.06)	$0.07	$1.04	$0.60	$0.77	$0.85	$0.89	$0.87	$0.94	$1.23	$0.82
Weighted Average Diluted Shares Outstanding	106.88M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M	119.99M
Weighted Average Basic & Diluted Shares Outstanding	106.80M	116.30M	113.30M	116M	114.90M	117.31M	105.96M	107.90M	103.52M	105.50M	106.37M

This table shows Corcept Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	31	28	35	47	30	20	35	19	24	-31	42
Consolidated Net Income / (Loss)	31	28	35	47	31	21	35	20	24	-32	43
Net Income / (Loss) Continuing Operations	31	28	35	47	31	21	35	20	24	-32	43
Total Pre-Tax Income	37	35	42	53	32	9.62	32	15	9.91	-45	46
Total Operating Income	32	30	36	47	25	3.42	27	10	4.49	-50	41
Total Gross Profit	134	144	161	180	179	155	191	203	200	162	252
Total Revenue	135	147	164	183	182	157	194	208	202	165	256
Operating Revenue	135	147	164	183	182	157	194	208	202	165	256
Total Cost of Revenue	1.88	2.54	2.52	2.87	2.96	2.40	3.43	4.60	2.55	2.88	4.06
Operating Cost of Revenue	1.88	2.54	2.52	2.87	2.96	2.40	3.43	4.60	2.55	2.88	4.06
Total Operating Expenses	102	115	126	133	154	151	164	193	195	212	211
Selling, General & Admin Expense	47	56	67	74	83	91	104	124	130	145	157
Research & Development Expense	55	59	59	59	70	61	60	69	65	66	54
Total Other Income / (Expense), net	5.14	5.49	6.00	6.35	6.70	6.20	5.02	5.02	5.42	4.89	4.63
Income Tax Expense	5.45	7.23	6.11	5.73	1.22	-11	-3.46	-4.43	-14	-13	2.94
Basic Earnings per Share	$0.29	$0.27	$0.34	$0.45	$0.29	$0.19	$0.33	$0.19	$0.24	($0.30)	$0.40
Weighted Average Basic Shares Outstanding	103.56M	102.79M	103.12M	103.37M	103.23M	104.11M	104.11M	103.55M	103.86M	104.44M	105.38M
Diluted Earnings per Share	$0.27	$0.25	$0.32	$0.41	$0.25	$0.17	$0.29	$0.16	$0.20	($0.30)	$0.36
Weighted Average Diluted Shares Outstanding	111.74M	109.92M	111.24M	113.72M	113.48M	119.82M	120.49M	119.44M	119.99M	104.44M	118.39M
Weighted Average Basic & Diluted Shares Outstanding	103.52M	104.11M	104.49M	104.78M	105.50M	106.04M	105.37M	105.19M	106.37M	107.35M	108.10M

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	16	11	-20	11	-10	45	1.43	-11	69	-7.89	-7.17
Net Cash From Operating Activities	3.13	18	61	116	136	152	168	120	127	198	142
Net Cash From Continuing Operating Activities	3.13	18	61	116	136	152	168	120	127	198	142
Net Income / (Loss) Continuing Operations	-6.41	8.14	129	75	94	106	113	101	106	141	100
Consolidated Net Income / (Loss)	-6.41	8.14	129	75	94	106	113	101	106	141	100
Depreciation Expense	0.16	0.09	0.11	0.24	0.70	0.53	1.07	1.26	1.04	0.80	1.15
Amortization Expense	0.02	0.02	0.01	-1.72	-0.27	3.02	7.49	3.57	-7.81	-10	-4.36
Non-Cash Adjustments To Reconcile Net Income	8.86	8.99	14	24	28	39	40	42	54	60	84
Changes in Operating Assets and Liabilities, net	0.50	1.16	-82	18	14	3.19	7.17	-28	-27	6.61	-38
Net Cash From Investing Activities	-0.02	-0.19	-73	-91	-118	-119	136	-114	91	-178	70
Net Cash From Continuing Investing Activities	-0.02	-0.19	-73	-91	-118	-119	136	-114	91	-178	70
Purchase of Property, Plant & Equipment	-0.02	-0.19	-0.42	-0.30	-1.09	-1.24	-0.47	-0.41	-0.14	-2.17	-0.21
Purchase of Investments	0.00	0.00	-103	-233	-299	-420	-313	-355	-329	-588	-320
Sale and/or Maturity of Investments	-	0.00	30	143	182	302	449	241	420	413	390
Net Cash From Financing Activities	13	-7.10	-7.95	-14	-29	12	-303	-17	-149	-28	-220
Net Cash From Continuing Financing Activities	13	-7.10	-7.95	-14	-29	12	-303	-17	-149	-28	-220
Repurchase of Preferred Equity	-	-	-	-	-	-	-	0.00	-145	0.00	0.00
Repurchase of Common Equity	-	0.00	0.00	-24	-31	-9.95	-296	0.00	0.00	-16	-173
Issuance of Common Equity	-	7.68	7.18	9.32	8.42	23	16	4.38	3.83	5.46	9.62
Other Financing Activities, net	22	-	0.00	0.00	-6.09	-1.07	-23	-22	-7.13	-18	-57
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-	0.36	-0.23	1.44
Cash Income Taxes Paid	0.06	0.04	0.38	1.35	6.74	11	9.10	40	48	60	13

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	24	14	-21	8.70	-9.62	-38	13	22	-4.64	-12	2.30
Net Cash From Operating Activities	5.89	24	41	74	59	4.77	44	54	38	-17	34
Net Cash From Continuing Operating Activities	5.89	24	41	74	59	4.77	44	54	38	-17	34
Net Income / (Loss) Continuing Operations	31	28	35	47	31	21	35	20	24	-32	43
Consolidated Net Income / (Loss)	31	28	35	47	31	21	35	20	24	-32	43
Depreciation Expense	0.21	0.12	0.13	0.32	0.28	0.46	0.29	0.29	0.29	0.60	0.86
Amortization Expense	-3.14	0.06	0.07	0.18	-11	-1.69	-2.82	-0.82	-0.90	-0.84	-0.71
Non-Cash Adjustments To Reconcile Net Income	13	-0.12	9.30	19	46	13	24	22	26	23	17
Changes in Operating Assets and Liabilities, net	-36	-4.07	-3.81	6.98	-6.79	-28	-13	13	-11	-7.95	-27
Net Cash From Investing Activities	17	-9.01	-60	-44	-64	-3.17	70	15	-12	4.54	-29
Net Cash From Continuing Investing Activities	17	-9.01	-60	-44	-64	-3.17	70	15	-12	4.54	-29
Purchase of Property, Plant & Equipment	-	0.00	-	-1.64	-0.12	-0.10	-0.06	-	-0.05	-0.20	-2.53
Purchase of Investments	-30	-78	-143	-223	-145	-115	-23	-37	-144	-52	-89
Sale and/or Maturity of Investments	47	69	83	181	80	112	93	52	132	57	62
Net Cash From Financing Activities	0.77	-0.54	-2.15	-21	-4.56	-40	-103	-46	-31	0.76	-2.04
Net Cash From Continuing Financing Activities	0.77	-0.54	-2.15	-21	-4.56	-40	-103	-46	-31	0.76	-2.04
Issuance of Common Equity	1.76	0.94	3.24	2.27	2.42	1.72	3.28	2.17	2.46	2.54	3.66
Other Financing Activities, net	-1.00	-1.01	-1.91	-12	-6.99	-14	-3.19	-6.12	-34	-1.78	-5.70
Effect of Exchange Rate Changes	-	-	-	-	-	0.36	-	-0.32	-0.03	-0.29	0.04

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	52	69	221	312	412	572	424	583	622	841	837
Total Current Assets	49	66	124	237	307	479	266	499	459	472	485
Cash & Equivalents	40	52	31	42	31	76	78	66	136	128	120
Short-Term Investments	-	0.00	58	165	245	365	146	365	233	256	252
Accounts Receivable	6.22	9.86	28	18	20	26	28	31	41	54	60
Inventories, net	1.68	2.33	4.58	4.73	5.42	4.91	4.99	6.10	7.73	12	13
Prepaid Expenses	0.64	1.96	2.67	7.74	6.04	6.70	10	16	28	22	41
Plant, Property, & Equipment, net	0.10	0.21	0.52	0.66	1.05	1.68	1.00	0.63	0.20	2.69	1.89
Total Noncurrent Assets	2.82	2.86	96	74	104	92	156	84	163	366	349
Long-Term Investments	-	0.00	15	0.00	39	36	112	4.95	57	220	160
Noncurrent Deferred & Refundable Income Taxes	-	0.00	77	63	46	32	27	61	91	131	168
Other Noncurrent Operating Assets	2.82	2.86	3.85	12	19	24	17	17	15	16	21
Total Liabilities & Shareholders' Equity	52	69	221	312	412	572	424	583	622	841	837
Total Liabilities	33	27	30	36	41	48	48	82	115	161	189
Total Current Liabilities	21	27	30	36	39	47	48	72	105	141	166
Accounts Payable	1.33	2.29	8.58	8.27	7.54	11	6.91	12	17	15	40
Accrued Expenses	4.43	10	21	27	30	35	40	59	87	125	125
Other Current Liabilities	-	-	-	0.00	1.56	2.05	0.53	1.14	0.15	0.83	1.08
Total Noncurrent Liabilities	13	0.00	0.00	0.24	2.29	0.90	0.41	9.10	10	20	23
Noncurrent Deferred Revenue	-	-	0.00	0.24	0.39	0.40	0.41	9.10	10	14	15
Other Noncurrent Operating Liabilities	-	-	-	0.00	1.90	0.50	-	-	0.00	6.11	7.59
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	18	41	191	276	371	523	376	502	507	680	648
Total Preferred & Common Equity	18	41	191	276	371	523	376	502	507	680	648
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	18	41	191	276	371	523	376	502	507	680	648
Common Stock	349	364	384	417	457	516	591	662	739	832	969
Retained Earnings	-330	-322	-193	-118	-24	82	195	296	403	544	643
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.08	-0.07	0.26	0.42	-0.23	-0.87	0.61	-0.22	2.26
Other Equity Adjustments	-	-	-	-	-	-	-	-	-	-	-967

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	618	525	594	656	715	784	846	802	824	815	889
Total Current Assets	534	433	432	503	561	467	439	443	541	426	440
Cash & Equivalents	300	172	112	150	129	137	90	103	125	109	111
Short-Term Investments	165	191	243	261	345	243	233	239	297	229	197
Accounts Receivable	33	33	35	62	54	60	62	65	70	39	77
Inventories, net	6.41	6.92	7.51	7.19	8.35	8.05	14	12	12	13	13
Prepaid Expenses	16	16	20	24	26	19	40	24	37	36	41
Plant, Property, & Equipment, net	0.46	0.41	0.30	0.13	1.47	2.93	2.54	2.35	2.09	3.17	5.13
Total Noncurrent Assets	83	92	162	152	152	314	405	356	280	386	444
Long-Term Investments	0.00	0.00	60	40	19	167	248	173	103	177	236
Noncurrent Deferred & Refundable Income Taxes	68	78	87	98	112	127	144	162	153	182	179
Other Noncurrent Operating Assets	15	13	15	14	21	20	13	21	25	27	29
Total Liabilities & Shareholders' Equity	618	525	594	656	715	784	846	802	824	815	889
Total Liabilities	88	103	132	108	118	145	163	166	192	177	183
Total Current Liabilities	79	93	122	97	101	126	143	145	172	149	154
Accounts Payable	11	7.98	17	13	19	19	28	24	34	33	15
Accrued Expenses	67	85	105	85	81	107	114	120	137	114	137
Other Current Liabilities	0.58	0.30	0.23	0.08	0.04	0.43	0.98	1.02	1.05	1.63	1.92
Total Noncurrent Liabilities	9.40	9.95	10	11	18	19	20	21	19	28	29
Noncurrent Deferred Revenue	9.40	9.95	10	11	12	13	14	16	14	15	15
Other Noncurrent Operating Liabilities	-	-	-	-	5.63	6.36	5.85	5.59	5.31	12	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	530	422	462	548	596	639	683	636	632	638	706
Total Preferred & Common Equity	530	422	462	548	596	639	683	636	632	638	706
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	530	422	462	548	596	639	683	636	632	638	706
Common Stock	680	696	723	758	781	806	863	901	934	1,002	1,049
Retained Earnings	312	340	371	430	466	513	564	599	619	612	655
Treasury Stock	-463	-	-	-641	-	-682	-745	-867	-923	-977	-998
Accumulated Other Comprehensive Income / (Loss)	-0.15	0.05	-0.23	0.26	0.08	1.57	0.69	2.29	2.34	0.92	0.44

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	89.39%	61.72%	95.77%	57.82%	21.99%	15.46%	3.42%	9.80%	20.04%	39.94%	12.79%
EBITDA Growth	77.30%	232.37%	541.68%	71.31%	29.16%	15.40%	-1.17%	-12.06%	-14.43%	26.70%	-67.35%
EBIT Growth	76.80%	227.03%	548.72%	74.51%	26.61%	12.79%	-5.01%	-9.90%	-4.75%	27.66%	-67.29%
NOPAT Growth	87.53%	522.35%	1,169.69%	-43.33%	23.01%	14.63%	8.49%	-12.25%	-7.01%	30.99%	-43.91%
Net Income Growth	79.58%	227.03%	1,486.27%	-41.60%	24.89%	12.56%	6.13%	-9.86%	4.66%	33.04%	-29.43%
EPS Growth	80.65%	216.67%	1,385.71%	-42.31%	28.33%	10.39%	4.71%	-2.25%	8.05%	30.85%	-33.33%
Operating Cash Flow Growth	111.43%	487.57%	231.33%	89.82%	17.68%	11.65%	10.48%	-28.33%	5.58%	55.91%	-28.39%
Free Cash Flow Firm Growth	92.96%	754.66%	316.87%	94.54%	13.49%	9.05%	5.14%	-38.32%	3.08%	65.44%	-77.37%
Invested Capital Growth	-11.12%	-18.88%	1,829.07%	-20.50%	-19.17%	-16.86%	-13.89%	63.08%	24.66%	-6.01%	50.98%
Revenue Q/Q Growth	13.43%	12.20%	22.72%	5.70%	7.38%	-0.61%	3.71%	1.06%	7.19%	7.40%	2.73%
EBITDA Q/Q Growth	21.92%	18.83%	45.97%	2.67%	9.75%	-3.17%	5.49%	-12.10%	6.08%	-9.88%	-20.78%
EBIT Q/Q Growth	21.57%	19.30%	46.01%	4.60%	9.91%	-4.12%	4.98%	-11.17%	9.35%	-4.47%	-31.68%
NOPAT Q/Q Growth	57.86%	49.19%	258.67%	-50.73%	8.55%	-2.36%	5.92%	-14.65%	14.22%	-2.03%	-14.55%
Net Income Q/Q Growth	43.10%	80.81%	264.86%	-50.30%	8.49%	-3.10%	5.69%	-13.17%	16.05%	-0.43%	-6.09%
EPS Q/Q Growth	50.00%	40.00%	258.62%	-50.41%	6.94%	-3.41%	7.23%	-13.00%	17.50%	-1.60%	-5.75%
Operating Cash Flow Q/Q Growth	228.49%	2.26%	50.01%	-2.83%	24.67%	-8.09%	9.35%	-11.76%	-17.80%	36.92%	-13.09%
Free Cash Flow Firm Q/Q Growth	70.59%	-1.36%	64.22%	-4.55%	31.84%	-11.81%	11.58%	-16.98%	-28.53%	60.06%	-54.60%
Invested Capital Q/Q Growth	-16.66%	113.91%	802.09%	9.94%	-17.21%	2.16%	-11.23%	-9.67%	73.61%	-16.19%	7.17%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.29%	97.47%	97.77%	97.92%	98.20%	98.42%	98.56%	98.66%	98.66%	98.39%	98.30%
EBITDA Margin	-12.39%	10.14%	33.24%	36.09%	38.21%	38.19%	36.50%	29.23%	20.84%	18.87%	5.46%
Operating Margin	-6.85%	12.52%	33.20%	35.62%	36.41%	36.23%	34.01%	28.03%	22.24%	20.29%	5.88%
EBIT Margin	-12.74%	10.01%	33.17%	36.68%	38.07%	37.19%	34.16%	28.03%	22.24%	20.29%	5.88%
Profit (Net Income) Margin	-12.74%	10.01%	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22.00%	20.92%	13.09%
Tax Burden Percent	100.00%	100.00%	244.52%	81.83%	80.72%	80.55%	90.01%	87.29%	85.21%	87.44%	149.94%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	103.16%	116.10%	117.92%	148.36%
Effective Tax Rate	0.00%	0.00%	-144.52%	18.17%	19.28%	19.45%	9.99%	12.71%	14.79%	12.56%	-49.94%
Return on Invested Capital (ROIC)	-40.82%	202.31%	282.65%	93.85%	144.15%	201.87%	259.22%	186.88%	124.78%	151.84%	70.04%
ROIC Less NNEP Spread (ROIC-NNEP)	201.25%	210.49%	282.82%	92.45%	142.59%	201.18%	259.11%	186.07%	121.36%	147.67%	64.31%
Return on Net Nonoperating Assets (RNNOA)	-43.99%	-175.12%	-171.50%	-61.55%	-115.04%	-178.17%	-234.20%	-163.77%	-103.73%	-128.03%	-55.02%
Return on Equity (ROE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.70%	25.03%	23.11%	21.05%	23.81%	15.01%
Cash Return on Invested Capital (CROIC)	-29.05%	223.15%	102.36%	116.69%	165.36%	220.29%	274.15%	138.92%	102.82%	158.03%	29.41%
Operating Return on Assets (OROA)	-14.81%	13.49%	36.51%	34.63%	32.23%	26.75%	25.11%	22.37%	17.81%	18.73%	5.34%
Return on Assets (ROA)	-14.81%	13.49%	89.27%	28.34%	26.02%	21.55%	22.60%	20.14%	17.62%	19.32%	11.88%
Return on Common Equity (ROCE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.70%	25.03%	23.11%	21.05%	23.81%	15.01%
Return on Equity Simple (ROE_SIMPLE)	-34.64%	19.67%	67.61%	27.33%	25.37%	20.26%	29.94%	20.21%	20.95%	20.78%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.41	10	129	73	90	103	112	98	91	120	67
NOPAT Margin	-4.79%	12.52%	81.18%	29.15%	29.39%	29.18%	30.61%	24.46%	18.95%	17.74%	8.82%
Net Nonoperating Expense Percent (NNEP)	-242.08%	-8.19%	-0.17%	1.40%	1.57%	0.69%	0.12%	0.80%	3.42%	4.17%	5.72%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	19.59%	18.04%	17.62%	10.37%
Cost of Revenue to Revenue	2.71%	2.53%	2.23%	2.08%	1.80%	1.58%	1.44%	1.34%	1.34%	1.61%	1.70%
SG&A Expenses to Revenue	73.48%	55.63%	39.21%	32.35%	32.75%	29.76%	33.43%	38.04%	38.20%	41.53%	58.93%
R&D to Revenue	30.66%	29.32%	25.36%	29.95%	29.04%	32.43%	31.11%	32.60%	38.22%	36.57%	33.48%
Operating Expenses to Revenue	104.14%	84.95%	64.57%	62.30%	61.79%	62.19%	64.54%	70.63%	76.42%	78.10%	92.41%
Earnings before Interest and Taxes (EBIT)	-6.41	8.14	53	92	117	132	125	113	107	137	45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.23	8.25	53	91	117	135	134	117	101	127	42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	29.28	19.48	10.79	5.59	3.73	5.81	6.08	4.36	6.61	7.77	5.65
Price to Tangible Book Value (P/TBV)	29.28	19.48	10.79	5.59	3.73	5.81	6.08	4.36	6.61	7.77	5.65
Price to Revenue (P/Rev)	10.77	9.91	12.95	6.14	4.51	8.59	6.25	5.44	6.94	7.82	4.81
Price to Earnings (P/E)	0.00	99.03	15.96	20.46	14.68	28.67	20.32	21.59	31.74	37.78	37.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.01%	6.26%	4.89%	6.81%	3.49%	4.92%	4.63%	3.15%	2.65%	2.68%
Enterprise Value to Invested Capital (EV/IC)	95.17	170.67	22.51	19.33	19.11	55.17	48.76	26.83	35.95	61.19	27.11
Enterprise Value to Revenue (EV/Rev)	10.52	9.46	12.29	5.32	3.48	7.24	5.33	4.35	6.06	6.93	4.11
Enterprise Value to EBITDA (EV/EBITDA)	0.00	93.26	36.98	14.73	9.12	18.96	14.60	14.90	29.08	36.72	75.22
Enterprise Value to EBIT (EV/EBIT)	0.00	94.50	37.06	14.50	9.15	19.47	15.60	15.53	27.24	34.15	69.83
Enterprise Value to NOPAT (EV/NOPAT)	0.00	75.57	15.14	18.24	11.85	24.81	17.41	17.80	31.97	39.05	46.57
Enterprise Value to Operating Cash Flow (EV/OCF)	168.93	41.83	32.12	11.55	7.84	16.86	11.62	14.54	23.01	23.61	22.03
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	68.51	41.81	14.67	10.33	22.74	16.46	23.94	38.80	37.52	110.90
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.49	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.22	-0.83	-0.61	-0.67	-0.81	-0.89	-0.90	-0.88	-0.85	-0.87	-0.86
Leverage Ratio	5.73	2.02	1.25	1.14	1.12	1.10	1.11	1.15	1.19	1.23	1.26
Compound Leverage Factor	5.73	2.02	1.25	1.14	1.12	1.10	1.11	1.18	1.39	1.45	1.87
Debt to Total Capital	59.78%	26.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	32.54%	26.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	27.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	40.22%	73.83%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-4.41	1.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	2.08	-4.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-2.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-11.41	1.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	5.37	-3.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-5.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.03	13.35	42.62	27.87	22.55	40.17	31.71	18.99	20.43	22.40	14.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.35	2.40	4.20	6.66	7.91	10.08	5.60	6.89	4.39	3.35	2.92
Quick Ratio	2.23	2.24	3.95	6.31	7.62	9.83	5.28	6.38	3.92	3.11	2.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.72	11	47	91	103	113	118	73	75	125	28
Operating Cash Flow to CapEx	18,411.76%	9,479.90%	14,542.96%	38,813.76%	12,510.75%	12,275.44%	35,797.87%	29,133.90%	91,394.96%	9,119.11%	67,296.68%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.16	1.35	1.10	0.94	0.85	0.72	0.74	0.80	0.80	0.92	0.91
Accounts Receivable Turnover	10.53	10.11	8.37	10.98	16.34	15.34	13.60	13.70	13.37	14.20	13.39
Inventory Turnover	0.94	1.03	1.03	1.12	1.08	1.08	1.07	0.97	0.94	1.08	1.03
Fixed Asset Turnover	301.11	536.77	440.39	428.38	359.51	259.72	273.42	491.57	1,165.16	468.13	332.56
Accounts Payable Turnover	0.85	1.14	0.65	0.62	0.70	0.62	0.60	0.57	0.44	0.66	0.47
Days Sales Outstanding (DSO)	34.68	36.09	43.63	33.26	22.34	23.79	26.84	26.65	27.31	25.71	27.27
Days Inventory Outstanding (DIO)	387.39	355.69	354.58	325.74	336.75	337.86	342.05	375.78	389.44	337.80	355.52
Days Payable Outstanding (DPO)	430.57	320.57	558.13	589.49	523.99	591.47	603.45	639.99	827.09	549.61	785.02
Cash Conversion Cycle (CCC)	-8.50	71.21	-159.93	-230.50	-164.90	-229.82	-234.56	-237.56	-410.34	-186.11	-402.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5.56	4.51	87	69	56	46	40	65	81	76	115
Invested Capital Turnover	8.52	16.16	3.48	3.22	4.90	6.92	8.47	7.64	6.58	8.56	7.94
Increase / (Decrease) in Invested Capital	-0.70	-1.05	82	-18	-13	-9.42	-6.45	25	16	-4.88	39
Enterprise Value (EV)	529	769	1,957	1,336	1,067	2,562	1,950	1,750	2,923	4,676	3,128
Market Capitalization	542	806	2,061	1,543	1,383	3,039	2,286	2,186	3,348	5,280	3,661
Book Value per Share	$0.17	$0.37	$1.67	$2.39	$3.25	$4.50	$3.25	$4.66	$4.92	$6.49	$6.16
Tangible Book Value per Share	$0.17	$0.37	$1.67	$2.39	$3.25	$4.50	$3.25	$4.66	$4.92	$6.49	$6.16
Total Capital	46	56	191	276	371	523	376	502	507	680	648
Total Debt	27	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-13	-37	-104	-207	-315	-477	-336	-437	-425	-603	-532
Capital Expenditures (CapEx)	0.02	0.19	0.42	0.30	1.09	1.24	0.47	0.41	0.14	2.17	0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.63	1.44	5.87	-5.51	-7.45	-9.69	-4.61	-4.91	-14	-53	-53
Debt-free Net Working Capital (DFNWC)	43	53	95	201	269	431	219	427	354	331	319
Net Working Capital (NWC)	28	38	95	201	269	431	219	427	354	331	319
Net Nonoperating Expense (NNE)	4.00	2.04	0.12	-2.17	-4.09	-2.74	-0.48	-3.10	-15	-21	-32
Net Nonoperating Obligations (NNO)	-13	-37	-104	-207	-315	-477	-336	-437	-425	-603	-532
Total Depreciation and Amortization (D&A)	0.18	0.11	0.12	-1.49	0.43	3.54	8.56	4.83	-6.77	-9.60	-3.21
Debt-free, Cash-free Net Working Capital to Revenue	5.24%	1.77%	3.69%	-2.19%	-2.43%	-2.74%	-1.26%	-1.22%	-2.92%	-7.78%	-6.93%
Debt-free Net Working Capital to Revenue	85.65%	65.15%	59.43%	80.10%	87.61%	121.80%	59.82%	106.20%	73.41%	49.01%	41.95%
Net Working Capital to Revenue	55.89%	47.12%	59.43%	80.10%	87.61%	121.80%	59.82%	106.20%	73.41%	49.01%	41.95%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	$0.07	$1.14	$0.65	$0.82	$0.92	$0.97	$0.95	$1.02	$1.35	$0.95
Adjusted Weighted Average Basic Shares Outstanding	109.66M	110.57M	113.53M	115.34M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M	103.86M
Adjusted Diluted Earnings per Share	($0.06)	$0.07	$1.04	$0.60	$0.77	$0.85	$0.89	$0.87	$0.94	$1.23	$0.82
Adjusted Weighted Average Diluted Shares Outstanding	109.66M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M	119.99M
Adjusted Basic & Diluted Earnings per Share	($0.06)	$0.07	$0.00	$0.00	$0.82	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.88M	112.94M	114.83M	114.72M	114.59M	117.31M	105.96M	107.90M	103.52M	105.50M	106.37M
Normalized Net Operating Profit after Tax (NOPAT)	-2.41	7.13	37	73	90	103	112	98	91	120	31
Normalized NOPAT Margin	-4.79%	8.76%	23.24%	29.15%	29.39%	29.18%	30.61%	24.46%	18.95%	17.74%	4.12%
Pre Tax Income Margin	-12.74%	10.01%	33.17%	36.68%	38.07%	37.19%	34.16%	28.91%	25.82%	23.92%	8.73%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	31.37%	32.89%	9.38%	263.07%	0.00%	0.00%	11.09%	173.52%

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	106,374,020.00	107,351,594.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	106,374,020.00	107,351,594.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.29	0.39
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	31.39%	38.95%	39.15%	47.69%	34.33%	7.09%	18.70%	13.75%	11.12%	4.89%	31.74%
EBITDA Growth	25.06%	88.89%	17.25%	84.46%	-48.57%	-86.93%	-32.55%	-79.42%	-73.78%	-2,380.96%	60.48%
EBIT Growth	40.76%	98.61%	20.31%	49.46%	-20.23%	-88.42%	-25.05%	-78.07%	-82.24%	-1,552.02%	54.83%
NOPAT Growth	75.34%	82.93%	22.79%	54.56%	-9.92%	-68.82%	-2.57%	-68.27%	-54.75%	-575.78%	30.65%
Net Income Growth	88.06%	74.83%	28.92%	50.47%	-1.94%	-25.99%	-0.96%	-58.34%	-21.00%	-254.58%	22.30%
EPS Growth	107.69%	78.57%	28.00%	46.43%	-7.41%	-32.00%	-9.38%	-60.98%	-20.00%	-276.47%	24.14%
Operating Cash Flow Growth	-82.37%	-8.48%	-2.61%	39.54%	907.30%	-78.41%	6.68%	-25.67%	-35.98%	-451.61%	-24.28%
Free Cash Flow Firm Growth	210.66%	25.96%	-156.32%	-105.36%	167.94%	6.07%	183.46%	-17.36%	-195.81%	-435.90%	-113.40%
Invested Capital Growth	24.66%	50.06%	77.84%	94.71%	-6.01%	16.17%	16.40%	18.06%	50.98%	8.94%	33.39%
Revenue Q/Q Growth	9.55%	8.42%	11.57%	11.45%	-0.36%	-13.57%	23.67%	6.79%	-2.66%	-18.42%	55.33%
EBITDA Q/Q Growth	12.58%	1.98%	20.59%	31.59%	-68.61%	-73.77%	522.46%	-59.85%	-60.00%	-1,385.84%	183.18%
EBIT Q/Q Growth	1.58%	-6.85%	20.65%	30.92%	-45.79%	-86.48%	680.88%	-61.69%	-56.09%	-1,205.44%	183.26%
NOPAT Q/Q Growth	0.34%	-13.25%	29.75%	36.85%	-41.52%	-69.97%	305.40%	-55.43%	-16.60%	-415.73%	211.33%
Net Income Q/Q Growth	-0.07%	-12.04%	27.83%	33.04%	-34.88%	-33.17%	71.07%	-44.04%	23.49%	-230.77%	235.35%
EPS Q/Q Growth	-3.57%	-7.41%	28.00%	28.13%	-39.02%	-32.00%	70.59%	-44.83%	25.00%	-250.00%	220.00%
Operating Cash Flow Q/Q Growth	-88.87%	303.53%	73.35%	79.27%	-19.68%	-91.35%	756.84%	23.99%	-29.43%	-143.62%	299.99%
Free Cash Flow Firm Q/Q Growth	-79.16%	-181.67%	-69.23%	81.39%	1,141.83%	-128.63%	250.36%	-126.16%	-750.57%	-60.15%	96.24%
Invested Capital Q/Q Growth	73.61%	19.09%	7.17%	-12.13%	-16.19%	47.18%	7.39%	-10.87%	7.17%	6.20%	31.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.61%	98.27%	98.46%	98.43%	98.37%	98.47%	98.23%	97.79%	98.74%	98.25%	98.41%
EBITDA Margin	21.23%	20.22%	21.85%	25.80%	8.13%	2.47%	12.42%	4.67%	1.92%	-30.22%	16.18%
Operating Margin	23.39%	20.09%	21.73%	25.53%	13.89%	2.17%	13.72%	4.92%	2.22%	-30.08%	16.12%
EBIT Margin	23.39%	20.09%	21.73%	25.53%	13.89%	2.17%	13.72%	4.92%	2.22%	-30.08%	16.12%
Profit (Net Income) Margin	23.16%	18.91%	21.67%	25.86%	16.90%	13.07%	18.08%	9.47%	12.02%	-19.26%	16.78%
Tax Burden Percent	85.19%	79.34%	85.32%	89.18%	96.20%	213.63%	110.91%	129.03%	245.09%	71.03%	93.59%
Interest Burden Percent	116.23%	118.62%	116.87%	113.62%	126.52%	281.56%	118.81%	149.16%	220.86%	90.15%	111.21%
Effective Tax Rate	14.81%	20.66%	14.68%	10.82%	3.80%	-113.63%	-10.91%	-29.03%	-145.09%	0.00%	6.41%
Return on Invested Capital (ROIC)	131.17%	103.45%	130.27%	207.34%	114.35%	30.40%	97.04%	47.34%	43.20%	-137.80%	88.94%
ROIC Less NNEP Spread (ROIC-NNEP)	130.16%	102.50%	129.07%	206.16%	113.10%	27.81%	95.94%	46.13%	40.85%	-138.35%	88.12%
Return on Net Nonoperating Assets (RNNOA)	-111.25%	-87.15%	-108.51%	-180.30%	-98.06%	-23.08%	-78.45%	-38.91%	-34.95%	113.74%	-69.60%
Return on Equity (ROE)	19.93%	16.30%	21.76%	27.03%	16.29%	7.32%	18.59%	8.43%	8.24%	-24.06%	19.34%
Cash Return on Invested Capital (CROIC)	102.82%	86.36%	76.72%	112.84%	158.03%	89.33%	80.99%	62.49%	29.41%	-35.86%	-19.11%
Operating Return on Assets (OROA)	18.73%	16.52%	19.98%	23.28%	12.82%	1.98%	12.96%	4.54%	2.02%	-27.85%	15.85%
Return on Assets (ROA)	18.54%	15.54%	19.92%	23.59%	15.61%	11.93%	17.08%	8.73%	10.91%	-17.83%	16.50%
Return on Common Equity (ROCE)	19.93%	16.30%	21.76%	27.03%	16.29%	7.32%	18.59%	8.43%	8.24%	-24.06%	19.34%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.54%	21.13%	22.20%	0.00%	19.61%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	27	23	30	42	24	7.30	30	13	11	-35	39
NOPAT Margin	19.92%	15.94%	18.54%	22.76%	13.36%	4.64%	15.22%	6.35%	5.44%	-21.06%	15.09%
Net Nonoperating Expense Percent (NNEP)	1.02%	0.95%	1.20%	1.18%	1.25%	2.59%	1.10%	1.21%	2.34%	0.54%	0.82%
Return On Investment Capital (ROIC_SIMPLE)	5.32%	-	-	-	3.58%	1.07%	4.65%	2.09%	1.70%	-5.44%	5.48%
Cost of Revenue to Revenue	1.39%	1.73%	1.54%	1.57%	1.63%	1.53%	1.77%	2.21%	1.26%	1.75%	1.59%
SG&A Expenses to Revenue	34.82%	38.33%	40.86%	40.40%	45.84%	57.67%	53.41%	59.71%	64.43%	88.15%	61.25%
R&D to Revenue	40.40%	39.85%	35.86%	32.50%	38.65%	38.63%	31.10%	33.16%	32.09%	40.18%	21.04%
Operating Expenses to Revenue	75.23%	78.18%	76.73%	72.90%	84.49%	96.30%	84.51%	92.87%	96.52%	128.33%	82.29%
Earnings before Interest and Taxes (EBIT)	32	30	36	47	25	3.42	27	10	4.49	-50	41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	29	30	36	47	15	3.88	24	9.69	3.88	-50	41
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.61	4.74	5.67	7.57	7.77	17.64	12.24	13.86	5.65	6.72	13.23
Price to Tangible Book Value (P/TBV)	6.61	4.74	5.67	7.57	7.77	17.64	12.24	13.86	5.65	6.72	13.23
Price to Revenue (P/Rev)	6.94	4.96	5.94	7.69	7.82	17.58	10.87	11.82	4.81	5.58	11.24
Price to Earnings (P/E)	31.74	22.15	27.07	34.42	37.78	90.94	58.97	83.67	37.29	91.86	172.18
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.15%	4.51%	3.69%	2.91%	2.65%	1.10%	1.70%	1.20%	2.68%	1.09%	0.58%
Enterprise Value to Invested Capital (EV/IC)	35.95	22.16	27.85	47.03	61.19	102.06	60.18	76.47	27.11	30.79	54.55
Enterprise Value to Revenue (EV/Rev)	6.06	4.10	5.07	6.82	6.93	16.75	10.15	11.11	4.11	4.91	10.58
Enterprise Value to EBITDA (EV/EBITDA)	29.08	18.74	24.14	30.35	36.72	113.05	80.86	156.85	75.22	0.00	1,695.52
Enterprise Value to EBIT (EV/EBIT)	27.24	17.60	22.59	29.91	34.15	103.55	71.30	125.56	69.83	0.00	1,372.30
Enterprise Value to NOPAT (EV/NOPAT)	31.97	21.04	26.86	35.09	39.05	105.19	67.33	104.74	46.57	0.00	655.76
Enterprise Value to Operating Cash Flow (EV/OCF)	23.01	17.19	23.36	29.65	23.61	63.98	39.90	50.39	22.03	31.32	80.12
Enterprise Value to Free Cash Flow (EV/FCFF)	38.80	30.79	46.47	55.07	37.52	122.80	79.93	132.51	110.90	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.85	-0.85	-0.84	-0.87	-0.87	-0.83	-0.82	-0.84	-0.86	-0.82	-0.79
Leverage Ratio	1.19	1.18	1.22	1.25	1.23	1.22	1.23	1.27	1.26	1.26	1.26
Compound Leverage Factor	1.39	1.40	1.42	1.42	1.56	3.44	1.46	1.89	2.79	1.13	1.40
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	20.03	17.02	19.80	22.39	21.96	46.49	30.64	29.94	14.09	16.75	33.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.39	5.18	5.57	3.70	3.35	3.07	3.06	3.14	2.92	2.86	2.86
Quick Ratio	3.92	4.86	5.23	3.49	3.11	2.69	2.81	2.85	2.60	2.53	2.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	-8.90	-15	-2.80	29	-8.36	13	-3.29	-28	-45	-1.68
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	4,515.54%	49,008.26%	4,930.77%	77,085.96%	0.00%	76,896.00%	-8,344.28%	1,326.86%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.82	0.92	0.91	0.92	0.91	0.94	0.92	0.91	0.93	0.98
Accounts Receivable Turnover	13.37	11.13	13.19	13.32	14.20	11.12	12.10	11.46	13.39	15.25	11.74
Inventory Turnover	0.94	1.12	1.12	1.26	1.08	1.00	1.13	1.31	1.03	0.99	1.11
Fixed Asset Turnover	1,165.16	1,780.71	604.36	388.96	468.13	513.44	374.91	295.05	332.56	269.20	222.11
Accounts Payable Turnover	0.44	0.64	0.62	0.56	0.66	0.53	0.54	0.50	0.47	0.44	0.73
Days Sales Outstanding (DSO)	27.31	32.79	27.68	27.39	25.71	32.84	30.18	31.85	27.27	23.94	31.08
Days Inventory Outstanding (DIO)	389.44	325.27	324.69	289.76	337.80	365.98	322.86	278.07	355.52	369.67	329.90
Days Payable Outstanding (DPO)	827.09	568.62	584.09	657.13	549.61	687.63	673.23	722.88	785.02	830.70	498.00
Cash Conversion Cycle (CCC)	-410.34	-210.56	-231.71	-339.97	-186.11	-288.80	-320.19	-412.96	-402.23	-437.09	-137.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	81	97	104	91	76	112	121	108	115	123	161
Invested Capital Turnover	6.58	6.49	7.03	9.11	8.56	6.55	6.38	7.45	7.94	6.54	5.89
Increase / (Decrease) in Invested Capital	16	32	45	44	-4.88	16	17	16	39	10	40
Enterprise Value (EV)	2,923	2,146	2,890	4,288	4,676	11,480	7,269	8,233	3,128	3,772	8,790
Market Capitalization	3,348	2,597	3,383	4,836	5,280	12,051	7,784	8,757	3,661	4,288	9,334
Book Value per Share	$4.92	$5.33	$5.73	$6.11	$6.49	$6.48	$6.00	$6.00	$6.16	$6.00	$6.57
Tangible Book Value per Share	$4.92	$5.33	$5.73	$6.11	$6.49	$6.48	$6.00	$6.00	$6.16	$6.00	$6.57
Total Capital	507	548	596	639	680	683	636	632	648	638	706
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-425	-451	-492	-548	-603	-571	-515	-524	-532	-515	-545
Capital Expenditures (CapEx)	0.00	0.00	0.00	1.64	0.12	0.10	0.06	0.00	0.05	0.20	2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-4.60	-13	-40	-53	-27	-44	-53	-53	-61	-22
Debt-free Net Working Capital (DFNWC)	354	406	460	341	331	295	298	369	319	277	286
Net Working Capital (NWC)	354	406	460	341	331	295	298	369	319	277	286
Net Nonoperating Expense (NNE)	-4.38	-4.36	-5.12	-5.66	-6.45	-13	-5.56	-6.48	-13	-2.96	-4.33
Net Nonoperating Obligations (NNO)	-425	-451	-492	-548	-603	-571	-515	-524	-532	-515	-545
Total Depreciation and Amortization (D&A)	-2.92	0.18	0.20	0.50	-10	0.46	-2.54	-0.53	-0.61	-0.24	0.16
Debt-free, Cash-free Net Working Capital to Revenue	-2.92%	-0.88%	-2.29%	-6.30%	-7.78%	-3.99%	-6.11%	-7.13%	-6.93%	-7.98%	-2.69%
Debt-free Net Working Capital to Revenue	73.41%	77.58%	80.77%	54.21%	49.01%	43.10%	41.68%	49.77%	41.95%	36.00%	34.41%
Net Working Capital to Revenue	73.41%	77.58%	80.77%	54.21%	49.01%	43.10%	41.68%	49.77%	41.95%	36.00%	34.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.29	$0.27	$0.34	$0.45	$0.29	$0.19	$0.33	$0.19	$0.24	($0.30)	$0.40
Adjusted Weighted Average Basic Shares Outstanding	103.56M	102.79M	103.12M	103.37M	103.23M	104.11M	104.11M	103.55M	103.86M	104.44M	105.38M
Adjusted Diluted Earnings per Share	$0.27	$0.25	$0.32	$0.41	$0.25	$0.17	$0.29	$0.16	$0.20	($0.30)	$0.36
Adjusted Weighted Average Diluted Shares Outstanding	111.74M	109.92M	111.24M	113.72M	113.48M	119.82M	120.49M	119.44M	119.99M	104.44M	118.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	103.52M	104.11M	104.49M	104.78M	105.50M	106.04M	105.37M	105.19M	106.37M	107.35M	108.10M
Normalized Net Operating Profit after Tax (NOPAT)	27	23	30	42	24	2.39	19	7.15	3.14	-35	39
Normalized NOPAT Margin	19.92%	15.94%	18.54%	22.76%	13.36%	1.52%	9.60%	3.45%	1.55%	-21.06%	15.09%
Pre Tax Income Margin	27.18%	23.84%	25.40%	29.00%	17.57%	6.12%	16.30%	7.34%	4.90%	-27.12%	17.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	123.62%	118.57%	113.59%	11.09%	31.81%	106.36%	162.96%	173.52%	307.29%	76.95%

Financials Breakdown Chart

Key Financial Trends

Corcept Therapeutics’ second-quarter 2026 results showed a sharp rebound from the first quarter, with revenue and profitability reaching new highs within the provided period. Revenue increased to $256.1 million, up 31.7% from $194.4 million in the second quarter of 2025 and 55.3% sequentially. Gross profit rose to $252.1 million, maintaining an exceptionally high gross margin of approximately 98.4%.

Operating income recovered to $41.3 million from a $49.6 million operating loss in Q1 2026. Net income attributable to common shareholders was $42.0 million, compared with a $31.2 million loss in the prior quarter and $34.6 million in Q2 2025. Basic EPS improved to $0.40 from $0.33 year over year, while diluted EPS increased to $0.36 from $0.29.

Revenue growth remains strong: Quarterly revenue increased from $101.7 million in Q3 2022 to $256.1 million in Q2 2026, indicating substantial expansion over the period.
Q2 2026 delivered a significant earnings rebound: The company moved from a Q1 loss to $43.0 million of consolidated net income in the latest quarter.
Profitability improved year over year: Operating income rose from $26.7 million to $41.3 million, while net income increased approximately 22% from Q2 2025.
Gross margins remain exceptionally high: Cost of revenue was only $4.1 million on $256.1 million of revenue, producing a gross margin above 98%.
Research spending declined sequentially and year over year: R&D expense fell to $53.9 million in Q2 2026 from $66.3 million in Q1 and $60.5 million in Q2 2025, helping support the return to operating profitability.
The balance sheet remains well capitalized: Cash, short-term investments and long-term investments totaled approximately $544.6 million at June 30, 2026, up from approximately $515.0 million a year earlier.
There is no apparent debt burden in the provided statements: Total liabilities were $182.9 million versus $705.8 million of equity, giving the company substantial financial flexibility.
Share repurchases have reduced the net share count over time: Treasury stock was $998.0 million at Q2 2026, compared with $866.9 million at Q2 2025, although equity-based compensation partially offsets this benefit.
Operating cash flow was positive but below the prior-year quarter: Q2 2026 generated $33.5 million of operating cash flow, compared with $43.9 million in Q2 2025, despite the increase in reported net income.
Working capital requires monitoring: Accounts receivable increased to $76.9 million from $64.6 million year over year, while prepaid expenses rose to $41.4 million from $24.0 million.
Operating expenses are rising rapidly: Total operating expenses increased to $210.8 million from $164.3 million in Q2 2025, with selling, general and administrative expense rising approximately 51% to $156.9 million.
Quarterly earnings remain volatile: The company reported a $31.8 million net loss in Q1 2026 after earning $24.3 million in Q4 2025 and $19.7 million in Q3 2025, making individual-quarter results difficult to project.
Cash generation did not fully match accounting earnings: Operating cash flow of $33.5 million was below net income of $43.0 million, partly reflecting a $26.6 million use of cash from operating assets and liabilities.
Investment activity continues to create cash-flow swings: Corcept purchased $89.0 million of investments and sold or matured $62.2 million during Q2, resulting in $29.2 million of net cash used in investing activities.
Share dilution remains a consideration: Q2 diluted weighted-average shares outstanding were 118.4 million versus 105.4 million basic shares, reflecting a sizable gap from equity awards or other dilutive securities.

Overall, the financial statements point to a company with strong revenue momentum, very high gross margins, significant liquidity and a debt-light balance sheet. However, the sharp increase in SG&A expense, uneven quarterly earnings and weaker operating cash flow relative to the prior-year period are important risks. Investors should watch whether Q2’s rebound can be sustained without further escalation in commercial and operating costs.

09/04/26 03:06 PM ETAI Generated. May Contain Errors.

Corcept Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Corcept Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Corcept Therapeutics' net income appears to be on an upward trend, with a most recent value of $99.65 million in 2025, falling from -$6.41 million in 2015. The previous period was $141.21 million in 2024. View Corcept Therapeutics' forecast to see where analysts expect Corcept Therapeutics to go next.

Corcept Therapeutics' total operating income in 2025 was $44.80 million, based on the following breakdown:

Total Gross Profit: $748.43 million
Total Operating Expenses: $703.63 million

Over the last 10 years, Corcept Therapeutics' total revenue changed from $50.29 million in 2015 to $761.41 million in 2025, a change of 1,414.2%.

Corcept Therapeutics' total liabilities were at $188.85 million at the end of 2025, a 17.3% increase from 2024, and a 465.3% increase since 2015.

In the past 10 years, Corcept Therapeutics' cash and equivalents has ranged from $31.06 million in 2017 to $135.55 million in 2023, and is currently $120.50 million as of their latest financial filing in 2025.

Over the last 10 years, Corcept Therapeutics' book value per share changed from 0.17 in 2015 to 6.16 in 2025, a change of 3,520.5%.

Related Companies

Financial statements for NASDAQ:CORT last updated on 7/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Financials

Financials Breakdown Chart

Key Financial Trends

Corcept Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Financials

Annual Income Statements for Corcept Therapeutics

Quarterly Income Statements for Corcept Therapeutics

Annual Cash Flow Statements for Corcept Therapeutics

Quarterly Cash Flow Statements for Corcept Therapeutics

Annual Balance Sheets for Corcept Therapeutics

Quarterly Balance Sheets for Corcept Therapeutics

Annual Metrics And Ratios for Corcept Therapeutics

Quarterly Metrics And Ratios for Corcept Therapeutics

Financials Breakdown Chart

Key Financial Trends

Corcept Therapeutics Financials - Frequently Asked Questions

When does Corcept Therapeutics' financial year end?

How has Corcept Therapeutics' net income changed over the last 10 years?

What is Corcept Therapeutics' operating income?

How has Corcept Therapeutics' revenue changed over the last 10 years?

How much debt does Corcept Therapeutics have?

How much cash does Corcept Therapeutics have?

How has Corcept Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools